Eli Lilly and Novo Nordisk are competing over $150B in future obesity drug sales. But behind the ad lawsuits and pipeline headlines, there’s a quieter battle: who gets to hire and keep the scientists, engineers, and executives who actually build this market.
The numbers tell two very different stories right now:
𝗟𝗶𝗹𝗹𝘆 𝗶𝘀 𝗶𝗻 𝗳𝘂𝗹𝗹 𝗴𝗿𝗼𝘄𝘁𝗵 𝗺𝗼𝗱𝗲
$27B pledged for four new U.S. manufacturing sites – 3,000 permanent jobs for engineers, scientists, and lab technicians, plus ~10,000 construction jobs
$50B+ in U.S. capital investment since 2020, $21B+ of it in Indiana alone
A new $4.5B injection into its Lebanon, Indiana LEAP campus, home to the Lilly Medicine Foundry (~400 new science/engineering roles)
A Boston R&D hub (Lilly Seaport Innovation Center) built specifically around RNA/DNA therapeutics talent
CEO David Ricks was pharma’s highest-paid CEO in 2025 at $36.7M – a 26% raise
𝗡𝗼𝘃𝗼 𝗡𝗼𝗿𝗱𝗶𝘀𝗸 𝗶𝘀 𝗰𝗼𝗻𝘁𝗿𝗮𝗰𝘁𝗶𝗻𝗴 𝗮𝗻𝗱 𝗿𝗲𝗯𝘂𝗶𝗹𝗱𝗶𝗻𝗴
Cut 9,000 jobs (11% of its workforce) in 2025 as Lilly ate into its obesity market lead
New CEO Mike Doustdar’s first major move: hiring freezes in non-critical areas, then a five-day return-to-office mandate to “move faster”
Boardroom churn – the Novo Nordisk Foundation moved to retake board control, several independent directors quit, and a candidate (Pfizer’s former R&D chief Mikael Dolsten) withdrew from a board race
Chief Medical Officer Dr. Zachary Roberts departed to become CEO of Allogene Therapeutics
Former CEO Lars Fruergaard Jørgensen was ousted after Novo stock fell ~52% from its peak – still exiting with ~$19.5M in pay
𝗪𝗵𝘆 𝘁𝗵𝗲 𝗰𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝗼𝗻 𝗼𝘃𝗲𝗿 𝗽𝗲𝗼𝗽𝗹𝗲 𝗺𝗮𝘁𝘁𝗲𝗿𝘀 𝘀𝗼 𝗺𝘂𝗰𝗵
Deloitte data shows obesity treatments have overtaken oncology as pharma’s biggest contributor to late-stage pipeline value – the first time in 16 years oncology hasn’t led. That means metabolic-disease scientists are now the most in-demand specialists in the industry, and it’s not just a two-horse race: Viking Therapeutics, Kailera, Pfizer, and a wave of Chinese biotechs are all competing for the same limited pool of GLP-1 expertise.
Even the drugs themselves have become a recruiting tool. Nearly a third of employees say they’d switch jobs for GLP-1 coverage, and employers increasingly frame it as a retention lever, not just a benefit line item.
The historical irony: Novo Nordisk’s own predecessor companies spent decades poaching researchers from each other before merging to stop competing for the same talent pool internally. Now Novo finds itself on the losing end of a very similar dynamic – this time with Lilly on the other side.
Lilly is building. Novo is rebuilding. And the scientists, engineers, and executives who choose between them may shape who ultimately leads the GLP-1 race.